Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) – Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for Vir Biotechnology in a research note issued on Sunday, November 3rd. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($4.02) per share for the year, down from their previous estimate of ($3.30). The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.48) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s Q4 2024 earnings at ($0.96) EPS, FY2025 earnings at ($4.25) EPS, FY2026 earnings at ($3.55) EPS and FY2027 earnings at ($0.90) EPS.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million during the quarter, compared to the consensus estimate of $5.54 million. During the same period in the previous year, the company posted ($1.22) EPS. The company’s revenue for the quarter was down 9.8% compared to the same quarter last year.
Check Out Our Latest Research Report on VIR
Vir Biotechnology Price Performance
NASDAQ:VIR opened at $9.64 on Wednesday. Vir Biotechnology has a 1 year low of $7.12 and a 1 year high of $13.09. The business has a fifty day moving average of $7.77 and a 200-day moving average of $8.88.
Hedge Funds Weigh In On Vir Biotechnology
Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Vir Biotechnology by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock worth $125,362,000 after acquiring an additional 78,216 shares in the last quarter. Millennium Management LLC lifted its stake in Vir Biotechnology by 94.6% in the 2nd quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock worth $11,108,000 after acquiring an additional 606,804 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Vir Biotechnology by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after acquiring an additional 6,359 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Vir Biotechnology by 10.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after acquiring an additional 58,360 shares in the last quarter. Finally, Empowered Funds LLC lifted its stake in Vir Biotechnology by 8.2% in the 1st quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock worth $4,640,000 after acquiring an additional 34,640 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.
Insider Activity at Vir Biotechnology
In related news, Director Janet Napolitano sold 12,190 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the completion of the transaction, the director now owns 11,616 shares in the company, valued at $90,604.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold 15,940 shares of company stock worth $127,410 in the last quarter. 15.60% of the stock is owned by company insiders.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Featured Stories
- Five stocks we like better than Vir Biotechnology
- Insider Buying Explained: What Investors Need to Know
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Comparing and Trading High PE Ratio Stocks
- Insider Buying Signals Upside for These 3 Stocks
- Compound Interest and Why It Matters When Investing
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.